A new web-based method for automated analysis of muscle histology by Cordula Pertl et al.
Pertl et al. BMC Musculoskeletal Disorders 2013, 14:26
http://www.biomedcentral.com/1471-2474/14/26TECHNICAL ADVANCE Open AccessA new web-based method for automated analysis
of muscle histology
Cordula Pertl1*, Markus Eblenkamp2,3, Anja Pertl1, Stefan Pfeifer2, Erich Wintermantel2, Hanns Lochmüller4,
Maggie C Walter1, Sabine Krause1† and Christian Thirion5†Abstract
Background: Duchenne Muscular Dystrophy is an inherited degenerative neuromuscular disease characterised by
rapidly progressive muscle weakness. Currently, curative treatment is not available. Approaches for new treatments
that improve muscle strength and quality of life depend on preclinical testing in animal models. The mdx mouse
model is the most frequently used animal model for preclinical studies in muscular dystrophy research.
Standardised pathology-relevant parameters of dystrophic muscle in mdx mice for histological analysis have been
developed in international, collaborative efforts, but automation has not been accessible to most research groups. A
standardised and mainly automated quantitative assessment of histopathological parameters in the mdx mouse
model is desirable to allow an objective comparison between laboratories.
Methods: Immunological and histochemical reactions were used to obtain a double staining for fast and slow
myosin. Additionally, fluorescence staining of the myofibre membranes allows defining the minimal Feret’s
diameter. The staining of myonuclei with the fluorescence dye bisbenzimide H was utilised to identify nuclei
located internally within myofibres. Relevant structures were extracted from the image as single objects and
assigned to different object classes using web-based image analysis (MyoScan). Quantitative and morphometric
data were analysed, e.g. the number of nuclei per fibre and minimal Feret’s diameter in 6 month old wild-type
C57BL/10 mice and mdx mice.
Results: In the current version of the module “MyoScan”, essential parameters for histologic analysis of muscle
sections were implemented including the minimal Feret’s diameter of the myofibres and the automated calculation
of the percentage of internally nucleated myofibres. Morphometric data obtained in the present study were in
good agreement with previously reported data in the literature and with data obtained from manual analysis.
Conclusions: A standardised and mainly automated quantitative assessment of histopathological parameters in the
mdx mouse model is now available. Automated analysis of histological parameters is more rapid and less time-
consuming. Moreover, results are unbiased and more reliable. Efficacy of therapeutic interventions, e.g. within the
scope of a drug screening or therapeutic exon skipping, can be monitored. The automatic analysis system MyoScan
used in this study is not limited exclusively to dystrophin-deficient mice but also represents a useful tool for
applications in the research of other dystrophic pathologies, various other skeletal muscle diseases and
degenerative neuromuscular disorders.
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Duchenne muscular dystrophy (DMD) is an inherited,
progressive disorder affecting striated and cardiac mus-
cles. It is caused by mutations in the dystrophin gene
[1,2], one of the largest genes in the human genome.
This gene encodes a large cytoskeletal protein called
dystrophin that links the cytoskeleton to the extracellu-
lar matrix [3-5]. DMD is the most prevalent X-linked re-
cessive neuromuscular disorder, affecting 1 in 3500 male
children. There is still no curative treatment available.
Current treatments for DMD are symptomatic and sig-
nificantly improve longevity and quality of life but hardly
prevent loss of muscle function [6]. Short-term prednis-
one treatment is recommended to preserve motor func-
tions in ambulant DMD patients [7].
A naturally occurring dystrophin-deficient mutant was
first described in 1984 in a colony of C57BL/10 mice
(C57BL/10ScSnJ) [8] and has since been referred to as
the “mdx mouse”. This mouse, now called C57BL/
10ScSn-Dmdmdx/J, is among the most frequently used
mouse models used in basic research. It carries a point
mutation in exon 23 of the mouse dystrophin gene
introducing a premature stop codon, which leads to the
loss of full-length dystrophin [8]. In the mdx mouse the
acute onset of myofibre necrosis occurs around 21 days
of age. The acute onset of dystrophic pathology with
high levels of necrosis provides a very sensitive assay to
specifically evaluate some effects of therapeutic interven-
tions designed to prevent or reduce myofibre necrosis.
Normal myofibres show peripheral nuclei, intact sarco-
lemma and non-fragmented sarcoplasm. Necrotic
muscle is characterised by infiltrating inflammatory cells,
hypercontracted myofibres and degenerating myofibres
with fragmented sarcoplasm. Regenerating rodent
muscle subsequently displays myofibres with internal
nuclei (regenerated myofibres). Internal nuclei are the
feature of regenerated rodent muscle. In other species,
including humans, the nuclei become peripheral and
they are not necessarily a marker of regeneration [9,10].
Cumulative skeletal muscle damage in young mdx mice
comprises of active myofibre necrosis as well as areas of
subsequent regeneration (new myofibres). Myonuclei of
newly regenerated myofibres of mdx mice remain in an
internal location for about 50–100 days. Subsequently,
3–4% of the myonuclei move to a peripheral subsarco-
lemmal position [11]. Myofibre size can be determined
by the analysis of the cross sectional area. Values for the
myofibre size may be distorted by the orientation of the
sectioning angle. This problem can be avoided by meas-
uring the minimal Feret’s diameter defined as the mini-
mum distance of parallel tangents at opposing borders
of the muscle fibre [12]. Dystrophic muscle typically dis-
plays a higher variability of the muscle fibre diameter as
compared to wild-type muscle. The variance coefficient(VC) of all muscle fibres’ minimal Feret’s diameters of a
given muscle cross-section provides a numerical value of
the myofibre size variability [12].
Subsequent to the acute onset of myofibre necrosis in
young mice, a low level of necrotic and regenerating (re-
cently necrotic) tissue, regenerated (with internal nuclei)
and some unaffected (intact) myofibres can be observed
in skeletal muscle from adult mdx mice. Necrotic, regen-
erating and regenerated muscles have distinct histo-
logical features [13]. mdx myofibres with internally
located nuclei are a reliable indicator of previously nec-
rotic/regenerated tissue. In older mice, Grounds et al.
propose that the area of muscle that has not succumbed
to necrosis exhibits a useful measure. The area of un-
affected myofibres indicates resistance of the myofibres
to damage. Unaffected myofibres look normal with per-
ipheral nuclei.
In a joint effort supported by TREAT-NMD, histo-
logical parameters to improve histology based preclinical
analysis were implemented (http://www.treat-nmd.eu/
downloads/file/sops/). Currently, there exists no auto-
mated and standardised analysis system that is available
to every laboratory. Analysis has to be carried out manu-
ally and therefore is biased to some degree.
Here, a globally accessible platform for histological
analysis was developed. This platform allows, for ex-
ample, comparability of histological evaluation and faster
and more reliable preclinical drug candidate testing for
DMD that can be applied to other degenerative neuro-
muscular disorders as well.
Methods
Mice
Mdx mice were obtained from Charles River Laborator-
ies, Brussels, Belgium. The wild type control mice
C57BL/10ScSnOlaHsd were purchased from Harlan La-
boratories, Blackthorn, UK. Male mice were sacrificed at
the age of 6 month by cervical dislocation. All animal
experiments were carried out according to the German
Animal Protection Law. The experiments were approved
and controlled by the responsible authorities (55.2-1-54-
2531-131-06, Regierung von Oberbayern, respectively
Staedtisches Veterinaeramt, Munich, Germany).
Histochemistry and immunohistochemistry
M. tibialis anterior (TA), M. soleus (Sol) and diaphragm
(DIA) muscles were collected from 6 month old male
C57BL/10 wild-type mice and mdx mice, respectively.
Each group consisted of ≥ 7 mice (control group: n = 7,
mdx: n = 8). Left and the right muscles of the hind limb
were used. The whole muscle CSA was imaged and ana-
lysed in order to obtain less biased results. Altogether,
about 2000 fibres were analysed for TA, about 3000 for
DIA and 700 for Sol. Muscles were mounted on
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Steinheim, Germany). The samples were snap-frozen in
isopentane cooled with liquid nitrogen and stored
at −80°C.
The following procedure involves the use of immuno-
logical and histochemical reactions, which result in
double staining for fast and slow myosin. Additionally,
fluorescence staining of the myofibre membranes allows
defining the minimal Feret’s diameter. The staining of
myonuclei with the fluorescence dye bisbenzimide H
(Hoechst 33258, Sigma-Aldrich) was utilised to identify
nuclei located internally within myofibres.
Eight μm serial cross-sections of the muscle of interest
were cut at a cryostat temperature of −25°C. We recom-
mend using gelatin coated slides to ensure proper at-
tachment of muscle sections during sequential staining.
Slides were cleaned in 70% ethanol (Carl Roth GmbH,
Karlsruhe, Germany) for 10 min and rinsed well in de-
ionised water for 20 min. 500 ml of a 0.5% gelatin solution
(Sigma-Aldrich) containing 0.05% chromium potassium
sulphate (Sigma-Aldrich) was prepared at 60°C and filtered
through standard filter paper. Slides were incubated in gel-
atine solution at 37-40°C for about 20 sec. Slides were
allowed to dry overnight in a dust free incubator at a max-
imal temperature of 37°C. Until slides are used, it is recom-
mended to store them at −20°C. Sections can be stored
at – 20°C up to a few months.
After one hour at room temperature, sections were
covered with 0.1% Triton X-100 (Sigma-Aldrich) in PBS
(Phosphate buffered saline; PAA Laboratories GmbH,
Pasching, Austria) solution, pH 7.3 for 15 min. Triton-X
was removed and the slides were allowed to drain for a
few minutes and were then arranged in humid chamber.
A 1:100 dilution of slow myosin antibody (Novocastra,
Newcastle upon Tyne, UK) in FCS (PAA Laboratories
GmbH, Pasching, Austria) was applied to the sections
and incubated at 4°C overnight. On the next day, the
slow myosin antibody was rinsed off with 0.1% Triton
X-100 in PBS and then washed in 0.1% Triton X-100 in
PBS for an additional 30 min with one buffer change.
Afterwards, the sections were covered with the second-
ary rabbit anti mouse IgG horseradish peroxidase
(DAKO, Glostrup, Denmark) diluted 1:100 in 0.1 M
lysine (Sigma-Aldrich), 40% Foetal Calf Serum (FCS) in
PBS for 90 min at room temperature. Again, the anti-
body was rinsed off and sections were washed in 0.1%
Triton X-100 in PBS for 30 min with one buffer change
refreshing the solution after 15 min. Sections were cov-
ered with DAB (3,3’-diaminobenzidine tetrahydrochlor-
ide, Sigma-Aldrich) Peroxidase Substrate Solution
[5 drops of 1% DAB (20x) added to 5 ml PBS, then
mixed with 5 drops of 0.3% H2O2 (20x)] and incubated
for 10 min. The DAB (20x) Peroxidase Substrate Solu-
tion was prepared as follows. 0.1 g of DAB was added to10 ml distilled water. 3–5 drops of 10 N HCl (Carl Roth
GmbH) were added until the solution turned light
brown and mixed for 10 min. Aliquots were stored
at −20°C.
Afterwards, sections were rinsed several times in tap
water, rinsed briefly in PBS and incubated in FCS for
10 min. Without washing, the second primary antibody
against fast myosin (NovoCastra), diluted 1:100 in FCS,
was applied and incubated for 60 min. It is important to
mention, that we obtained identical results when we
interchanged the primary antibodies for slow and fast
myosin. Next, the antibody was removed and slides were
washed as described before. The sections were incubated
with the same secondary antibody mentioned before to-
gether with 100 μg/ml Alexa Fluor 488 conjugated
WGA (wheat germ agglutinin; Life Technologies GmbH,
Darmstadt, Germany). After washing, the sections were
covered with Vector SG visualisation solution (Vector
Laboratories, Burlingame, CA, USA) for 10 min. 3 drops
of chromogen were mixed with 3 drops of hydrogen per-
oxide substrate. The slides were washed in PBS for
5 min, followed by an incubation in 10 ng/ml Hoechst
33258 (bisbenzimide H) in PBS (50 μl each slide) for
5 min. Afterwards, slides were rinsed in PBS for
2–5 min, followed by a short rinse in distilled water.
Nuclear counter stain was performed in Carazzi’s haema-
toxylin for 30 sec, blued up in running tap water for 2 min
and mounted in mounting medium (DakoCytomation
Fluorescent Mounting Medium, Dako). We utilised the nu-
clear counter stain to allow for double-check if nuclei were
correctly identified. Carazzi’s hematoxylin solution was pre-
pared as follows. 0.2 g hematoxylin (Merck KGaA, Darm-
stadt, Germany) was dissolved in distilled water at 50°C.
The solution was cooled to room temperature and 0.04 g
NaIO3 (Sigma-Aldrich), 10 g AlK(SO4)2 · 12 H2O (Sigma-
Aldrich), and 40 ml glycerol (Merck) was added. Images
were acquired using a Zeiss Axiovert 200 M fluorescence
microscope and a Zeiss AxioCam HR photo camera.
Images were taken at 20x magnification.
To register for the analysis service, the user is required
to contact S.CO LifeScience GmbH (Munich, Germany)
to get access to a personal web portal, which provides
the MyoScan analysis module. The user is asked to pur-
chase a volume package for this module type, which
defines the number of analyses available. The web based
analysis service is accessible worldwide any time. Cur-
rently, the costs for the analysis of one specimen are
5–10 €, depending on the prepaid volume package size.
Technically, there is no limitation for the file size, apart
from general limitations for upload processes via the
world wide web. However, if a single file exceeds 20 MB
the provider should be informed to ensure proper data
handling. All common image file formats including .tif,
.jpg, and .gif are supported. The maximum upload file
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user has purchased.
Quantitative assessment of muscle histology
Automatic quantitative analysis of muscle histology was
performed with a specially designed module MyoScan
for the web-based image analysis system S.CORE by
S.CO LifeScience GmbH (http://www.sco-lifescience.com/
technology.php5). Three different images of the observed
section in the histological slice were taken: 1. Green fluor-
escent WGA staining for display of the myofibre boundar-
ies, 2. Blue fluorescent Hoechst 33258 staining for display
of the nuclei, 3. MHC (myosin heavy chain)-double stain-
ing for display of all myofibres which are positive for my-
osin slow type heavy chain or myosin fast type heavy
chain, respectively. In the first image, all membrane struc-
tures were separated from background, leading to a mask
for the individual muscle myofibres. This mask was super-
imposed first with the Hoechst 33258 image to identify
the nuclei within myofibres resulting in a second mask
displaying the relevant nuclei.
Both masks were superimposed with the MHC-double
staining image to merge all relevant information in a single
image (membrane: white, nuclei: black, MHC-double stain-
ing: colored). Based on the Cognition Network Techno-
logy of Definiens AG, Munich, relevant structures were
extracted from the image as single objects and assigned to
different object classes. This allows a detailed analysis of
the relevant quantitative and morphometric data, e.g. num-
ber of nuclei per fibre and minimal Feret’s diameter.
Finally, each myofibre was automatically annotated
with an ID and all data summarised in an Excel file, both
as single data for each myofibre and as mean values. The
variance coefficient (VC) was determined using the fol-
lowing formula:
VC ¼ 1000
standard deviation of muscle myofibre
minimal Feret diameters
mean muscle myfibreminimal Feret0s diameter
:
Importantly, high image quality is essential to ensure op-
timal analysis. Therefore, folds, freezing artefacts, uneven
or pale staining should be avoided as far as possible. Inten-
sive, high quality staining of the myofibre boundaries is es-
pecially important. In our study labeling with WGA
worked very well. However, any other membrane or extra-
cellular matrix marker may be used instead. Nevertheless,
the user is able to check each individual image processing
step generated by MyoScan since result files are provided
by the analysis system for individual processing if needed.
Thus, the user can identify regions of the sections that are
not appropriate for analysis. It is always possible to
exclude any inappropriate data from analysis. Moreover,
MyoScan applies an algorithm which screens generatedimages whether identified fibers fit the form and size com-
pared to threshold parameters previously defined by the
user.
To verify the data generated by MyoScan, manual ana-
lysis was carried out on whole muscle sections of TA
muscle (n = 4) of 6 month old mdx mice using ImageJ
software IJ 1.46r [14]. All sections were analysed for both
minimal Feret’s diameter and internally nucleated fibres.
Statistical analysis
Statistical analysis was performed using SPSS Statistics
17.0 software (SPSS GmbH Software, Munich, Germany)
and MedCalc for Windows, version 12.3.0.0 (MedCalc
Software, Mariakerke, Belgium) for comparison of the
data generated by MyoScan with the manual analysis of
muscle sections. All data sets were tested for normal dis-
tribution using the Kolmogorov–Smirnov test. Those
data subsets that showed a normal distribution were
analysed by Student’s t-test.
Results
Quantitative assessment of histological parameters in
muscle sections of wild-type and mdx mice
Percentage of muscle fibres with internal nuclei, mean min-
imal Feret’s diameter, variance coefficients and fibre size
distribution were determined in three well-characterised
muscles of wild-type and mdx mice: the diaphragm (DIA),
M. soleus (Sol) and M. tibialis anterior (TA). These para-
meters were measured at 6 months of age on muscle sec-
tion staining. Figure 1 shows representative images of a
M. soleus section of a male mdx mouse immunodetected
by MHC-double staining. While Figure 1A displays the
staining with antibodies against myosin slow (brown fibres)
and fast (blue fibres) type heavy chain, Figure 1B represents
the staining of the fibre membrane with wheat germ agglu-
tinin and Figure 1C shows the staining of the myonuclei
with Hoechst 33258 on the same section. Figure 2 shows
representative, processed images of a 6 months old male
C57BL/10 mouse (Figure 2A) compared to an age-matched
male mdx mouse (Figure 2B). Yellow areas indicate myofi-
bres with peripheral nuclei (green dots), orange areas indi-
cate myofibres with internalised nuclei (blue dots). Finally,
numbers, which identify the myofibres’ ID, are automatic-
ally annotated. After analysis, resulting data are sum-
marised in an Excel file and can be used for further
statistical analysis. The provided data set comprises the
image with and without annotations. The first histological
parameter we determined was the percentage of muscle
fibres with internalised nuclei.
Significantly higher percentage of myofibres with
internally located nuclei in mdx mice
Myofibres of DIA, Sol and TA with internalised nuclei
were rarely seen in C57BL/10 wild-type mice. They
Figure 1 Representative MHC-double staining. (A) Myosin heavy chain (MHC)-double staining of a M. soleus (Sol) section obtained from a
mdx-mouse. Slow myosin heavy chain fibres are displayed in brown and fast myosin heavy chain fibres are blue. (B) Wheat germ agglutinin
staining (WGA staining) of the same section as in (A). WGA binds to N-acetylglucosamine and sialic acid residues at the myofibre membrane. (C)
Nuclear staining with Hoechst 33258 of the same section as in (A) and (B).
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muscle fibres analysed (Figure 3B). Compared to the
wild-type mice, DIA, Sol and TA muscles of mdx mice
contained 35.94 ± 5.93%, 56.23 ± 10.82% and 65.35 ±
4.83% myofibres with internalised nuclei, respectively
(Figure 3A).
The mean minimal Feret’s diameter is significantly
reduced in diaphragm of mdx mice
The minimal ‘Feret’s diameter’ is the morphometric par-
ameter that changes the least with the orientation of the
sectioning angle and thus was used to avoid biased
results. The minimal Feret’s diameter is the most robust
parameter in order to measure muscle fibre size and to
determine the fibre size variance coefficient (VC) com-
pared to other parameters like area, minimal inner diam-
eter or perimeter [12, TREAT-NMD SOP (ID) number:
DMD_M.1.2.001].
The mean minimal Feret’s diameter of wild-type mice
yielded 27.87 ± 9.23 μm (DIA), 36.0 ± 11.48 μm (Sol)
and 38.11 ± 14.03 μm (TA) while mdx mice revealed aFigure 2 Representative images processed by the S.CORE module “M
C57BL/10 mouse. (B) Image of a 6 months old male mdx mouse. Yellow ar
mark myofibres with internalised and internal nuclei (blue dots). Each myof
in an Excel file (data not shown).mean fibre size of 24.82 ± 8.07 μm (DIA), 37.36 ±
13.91 μm (Sol) and 37.96 ± 16.28 μm (TA) (Figure 3B).
The difference in mean minimal Feret’s diameter be-
tween the diaphragm of wild-type and mdx mice is sig-
nificant (p = 0.003). This observation is indicative of a
higher number of smaller fibres, which is characteristic
for newly formed muscle fibres during repeated cycles of
regeneration and degeneration as well as for atrophic
fibres [8].
M. tibialis anterior and M. soleus reveal an increased
variance coefficient in mdx mice
Dystrophic muscles display a high degree of variability
in the myofibre size because of a higher number of smal-
ler fibres and the occurrence of hypertrophic fibres. This
parameter is highly sensitive and is used routinely for
detecting differences between dystrophic and healthy
muscles [12].
Muscles of mdx mice showed a significantly higher
variance coefficient in TA muscle compared to age-
matched wild-type mice (C57BL/10: 362.10 ± 62.70,yoScan” without annotations. (A) Image of a 6 months old male
eas identify myofibres with peripheral nuclei (green dots), orange areas
ibre is automatically annotated with an ID and all data is summarised
Figure 3 Histological parameters in wild type and mdx mice. (A) Percentage of muscle fibres with internalised nuclei determined in the
diaphragm, M. soleus and M. tibialis anterior of wild type (black bars) and mdx mice (white bars) at 6 month of age. (B) Mean minimal Feret’s
diameter determined in the diaphragm, M. soleus and M. tibialis anterior of wild type (black bars) and mdx mice (white bars) at 6 month of age.
(C) Mean variance coefficient determined in the diaphragm, M. soleus and M. tibialis anterior of wild-type (black bars) and mdx mice (white bars)
at 6 month of age. (D-F) Fibre size distribution determined as percentage of the total fibre number in the diaphragm (D), M. soleus (E) and M.
tibialis anterior (F) of wild-type (black bars) and mdx mice (white bars) at 6 month of age. Data are shown as mean ± SD; n ≥ 7 mice; 1300–4300
myofibres per group; *p < 0.05, **p < 0.001 unpaired t-test.
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mdx mice, we observed a higher variance coefficient not
significantly different to wild-type mice (C57BL/10:
305.02 ± 87.04, mdx: 371.04 ± 53.53) (Figure 3C). By
contrast, variance coefficients in diaphragm are very
similar (C57BL/10: 330.74 ± 26.43, mdx: 322.74 ±
26.97.53) (Figure 3C).In mdx mice a shift towards a higher number of smaller
myofibres was observed
The analysis of the fibre size distribution revealed a ten-
dency of a shift towards a higher number of smaller
myofibres in mdx mice compared to C57BL/10 mice.
While the fibre size distribution in Sol was very similar
in both groups (Figure 3E), DIA and TA showed
Figure 4 The Bland-Altman procedure confirms equivalence
between manual and MyoScan analysis. Methodological
comparison of measurement of minimal Feret’s diameter (A) and
percentage of internally nucleated myofibres (B).
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had significant more myofibres below average size in a
range of 10 to 20 μm than wild-type mice (C57BL/10:
19.05 ± 4.64%, mdx: 32.00 ± 4.57%, p = 0.0001). At the
same time, the number of larger myofibres in the range be-
tween 30 and 50 μm were significantly reduced. C57BL/10
showed a percentage of 24.40 ± 9.24% fibres in the range of
30 to 40 μm and mdx 15.55 ± 2.47% (p = 0.02). In the range
of 40 to 50 μm, C57BL/10 mice showed a percentage of
7.00 ± 2.44% fibres and mdx mice 4.16 ± 1.67% (p = 0.02).
In TA, a significant decrease of the number of myofibres
was observed only in the range of 40 to 50 μm (C57BL/10:
20.63 ± 3.13%, mdx: 16.36 ± 4.06%, p = 0.04). In TA of mdx
mice, the number of smaller myofibres between 10 and
20 μm were not significantly increased (C57BL/10: 9.86 ±
5.31%, mdx: 12.22 ± 4.05%) and the number of fibres in the
range between 30 and 40 μm (C57BL/10: 25.93 ± 7.40%,
mdx: 21.63 ± 3.94%) were not significantly reduced as com-
pared to C57BL/10 mice (Figure 3F).
Bland-Altman analysis of the parameters minimal Feret’s
diameter and the percentage of fibres with internalised
nuclei determined manually and generated by MyoScan
Results obtained from manual analysis of whole muscle sec-
tions of TA muscle (n = 4) of 6 month old mdx mice were
compared to results received form automatic analysis of the
same muscle sections using MyoScan. To this end, we gen-
erated a Bland-Altman plot [15-17] for both parameters,
minimal Feret’s diameter (Figure 4A) and the percentage of
fibres with internalised nuclei (Figure 4B) using the Med-
Calc software program. The plot displays the average of the
paired values from each method on the x-axis and the dif-
ference of each pair of readings on the y-axis. The Bland-
Altman plot is recommended to assess the relative agree-
ment between two analytical methods [16]. The mean dif-
ference in values obtained with the two methods is called
the bias [17]. Method comparison of the parameter min-
imal Feret’s diameter yields a bias of −0.9 μm (Figure 4A)
and regarding the parameter percentage of internally
nucleated fibres we observed a bias of −1.7% (Figure 4B).
The limits of agreement represent the range of values
in which there is agreement between both methods for
approximately 95% of the values [17]. For the minimal
Feret’s diameter, the Bland-Altman plot displays the
upper limit of agreement at 5.3 μm and the lower limit
at −7.2 μm (Figure 4A). For the determination of inter-
nalised nuclei, Figure 4B shows an upper limit of agree-
ment at 8.4% and a lower limit of agreement at −11.8%,
whereas about 76% of the sample are below 5.0% and
are located close to the line indicating the bias of −1.7%.
Discussion
We performed simultaneous fluorescence staining of the
myofibre membrane by fluorescence dye conjugatedwheat germ agglutinin and of the nuclei by Hoechst
33258. Thus, we determined the percentage of internally
nucleated fibres and the fibre size variance coefficient. In
order to evaluate regeneration and necrosis, it is import-
ant to consider the age of the mdx mice as different
histological features change with age [13]. Myofibres
with internal nuclei are a reliable indicator of previously
necrotic/regenerated tissue. Though, internal nuclei can-
not indicate how often a muscle has undergone necrosis
and subsequent regeneration. Rather, the area of muscle
that was not affected by necrosis represents the favoured
measure in studies of older mice, since this indicates re-
sistance of the myofibres to damage.
In this study, we validated the MyoScan analysis mod-
ule by comparing wild-type C57BL/10 mice with mdx
mice, since our results were similar to earlier findings in
the literature [11,12]. C57BL/10 mice showed hardly any
internally nucleated fibres in contrast to mdx mice,
where we identified up to 65% fibres with internal
Pertl et al. BMC Musculoskeletal Disorders 2013, 14:26 Page 8 of 9
http://www.biomedcentral.com/1471-2474/14/26nuclei. Louboutin et al. (1993) reported a percentage of
about 40% internally nucleated myofibres in diaphragm
of 120 and 270 days old mdx mice, a value similar to
our findings (35.94 ± 5.93%). In TA and Sol they
observed about 70% and 65% compared to 65.35 ±
4.83% and 56.23 ± 10.82% in our study. A difference of
10% in the percentage of internally nucleated fibres in
Sol compared to previous findings in the literature and
the higher standard deviation of 10.82% may be due to
the fact, that only 700 fibres were analysed in Sol muscle
since the CSA of this muscle is smaller than that of DIA
or TA.
Moreover, the fibre size distribution analysed in DIA
and TA revealed the same shift towards a greater num-
ber of smaller myofibres in the range of 10 to 20 μm
and a loss of larger myofibres in mdx mice compared to
control mice as was found in our study [11]. Concerning
the fibre size variance coefficient, wild-type mice pre-
sented lower values when compared to mdx mice. In
TA, a significant higher variance coefficient was
observed in mdx mice. These findings are compatible
with the assumption that in mdx mice subsequent re-
generation causes the appearance of newly regenerated
myofibres in which nuclei remain in an internal location
for a few months and of a higher variability of fibre sizes
[12]. In addition to comparing our data with previous
findings in literature, we conducted a methodological
comparison between manual analysis and the MyoScan
method in TA muscle sections (n = 4) of 6 month mdx
mice using the Bland-Altman procedure.
The mean difference in values obtained with the two
methods is called the bias [17]. Biases for both para-
meters, the minimal Feret’s diameter and the percentage
of internally nucleated fibres, are relatively close to zero
(Figure 4) confirming that automated and manual ana-
lysis generate very similar results. The Bland-Altman
plot for the percentage of internally nucleated fibres
shows a slightly higher bias than for the Feret’s diameter
(Figure 4B). However, the difference is not large enough
to be clinically important, since the discrepancy between
both methods is less than 5.0% for about 76% of the
samples. The biases and limits of agreement for both
parameters are within a very small range that we assume
to be acceptable for nonclinical applications. In conclu-
sion, both methods are equally well suited to evaluate
the analysed parameters. Since we examined only
6 month old mice, additional analysis in mdx mice of
different age will be required. The automatic MyoScan
analysis tool has already been successfully applied in a
recent study where the efficacy of carboanhydrase inhi-
bitors for treatment of a DMD model was assessed [18].
The method revealed a reduction of internally nucleated
fibres in M. tibialis anterior of mdx mice treated with
carboanhydrase inhibitors and allowed to identifychanges of the fibre size variation [18]. The efforts of the
TREAT-NMD consortium to set standards in preclinical
development and animal models for the development of
new therapeutic treatments in neuromuscular disorders
resulted in the publication of guidelines and implemen-
tation of histological parameters for the mdx mouse
[13,19]. An initial set of recommended histopathological
parameters was implemented in MyoScan, which is able
to be upgraded and represents an automatic image ana-
lysis system available on a platform for objective and
quantitative histological analysis of muscle sections.
Here, we provide protocols for a standardised and auto-
mated method to assess the percentage of fibres with
internalised nuclei and the variance coefficient. More-
over, the degree of fibrosis represents an additional par-
ameter, which can be used to specify potentially
beneficial treatment. Furthermore, assessing the fibre
type distribution might be of interest. The described
MHC-double staining provides all necessary information
for the analysis of these parameters and allows an up-
grade of the developed method. Any colour change is
dependent on the proportion of each MHC isoform.
While co-expression of slow and fast myosin is detect-
able by double staining, very low levels of co-expression
may not be detectable. In order to identify hybrid fibres
with low levels of co-expression, we suggest separating
the MHC-double staining described here. MHC staining
may be done separately for slow or fast myosin while
still assessing the percentage of fibres with internalised
nuclei and the variance coefficient.
Despite the fact that muscle pathology for dystrophin
deficiency differs between the mdx mouse model and
human patients, the mdx mouse model is the most im-
portant animal model for preclinical studies in DMD re-
search [19,20]. In addition to the outcome measures
discussed here, the histological extent of fibrosis or func-
tional analysis like muscle force measurements provide
essential data to assess the dystrophic phenotype. Fur-
thermore, histological changes in the mdx mouse model
are often used as a surrogate marker for potential thera-
peutic benefit. The determination of fibre size variability
is challenging. Consequently, the quantitative assessment
of the fibre size variability is rarely performed. In this
study, we validated a standardised and mainly automated
quantitative assessment of histopathological parameters
in the mdx mouse model that provides rapid and un-
biased results.
Conclusions
The analysis of dystrophic pathology on histological
muscle sections is highly interpretative and thus can vary
between individuals and laboratories. Moreover, a statisti-
cally sound and secure histological analysis of muscle sec-
tions entails an intense technical and time-consuming
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vided in each laboratory on a regular basis. Therefore, a
standardised and mainly automated quantitative assess-
ment of histopathological parameters in the mdx mouse
model is desirable to allow an objective comparison be-
tween laboratories. The developed method allowed us to
perform a histological analysis of pathological changes of
muscle fibres, particularly of the percentage of internally
nucleated fibres and of the fibre size variance coefficient
determined by the Feret’s diameter. Those parameters de-
scribe the process of degeneration and regeneration in
mdx mice. The web-based image analysis system S.CORE
with its specially designed module MyoScan offers a con-
venient solution, because it is generally available for all la-
boratories and enables an automated quantitative analysis
of both parameters. The automated analysis system
MyoScan used in this study is not limited exclusively to
dystrophin-deficient mice, but also represents a useful tool
for applications in the research of other dystrophic path-
ologies and in various other skeletal muscle diseases.
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